ScholarIQanswers from OpenAlex & ORCID
Kurt A. Schalper
ResearcherPublications, citations & collaboration network
Kurt A. Schalper is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Kurt A. Schalper have?
ScholarIQindexed works
Kurt A. Schalper has 639 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Kurt A. Schalper have?
ScholarIQcitation count
Kurt A. Schalper has 25,639 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Kurt A. Schalper?
ScholarIQh-index
Kurt A. Schalper has an h-index of 71 in OpenAlex.
What is the i10-index of Kurt A. Schalper?
ScholarIQi10-index
Kurt A. Schalper has an i10-index of 138 in OpenAlex.
What is the ORCID of Kurt A. Schalper?
ScholarIQorcid
The ORCID for Kurt A. Schalper is on the source record.
What is the OpenAlex record for Kurt A. Schalper?
ScholarIQopenalex
The OpenAlex for Kurt A. Schalper is on the source record.
What are the most-cited papers on Kurt A. Schalper?
ScholarIQmost cited works
Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
Hira Rizvi, Francisco Sánchez-Vega, Konnor La, Walid K. Chatila, Philip Jonsson, Darragh Halpenny, Andrew J. Plodkowski, Niamh M. Long, Jennifer L. Sauter, Natasha Rekhtman, Travis J. Hollmann, Kurt A. Schalper, Justin F. Gainor, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub, Jedd D. Wolchok, Alexandra Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila, Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, Matthew D. Hellmann
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
Joseph McLaughlin, Gang Han, Kurt A. Schalper, Daniel Carvajal‐Hausdorf, Vasiliki Pelekanou, Jamaal Rehman, Vamsidhar Velcheti, Roy S. Herbst, Patricia LoRusso, David L. Rimm
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
Scott Gettinger, Jungmin Choi, Katherine Hastings, Anna Truini, Ila Datar, Ryan Sowell, Anna Wurtz, Weilai Dong, Guoping Cai, Mary Ann Melnick, Victor Y. Du, Joseph Schlessinger, Sarah B. Goldberg, Anne C. Chiang, Miguel F. Sanmamed, Ignacio Melero, Jackeline Agorreta, Luis M. Montuenga, Richard P. Lifton, Soldano Ferrone, Paula Kavathas, David L. Rimm, Susan M. Kaech, Kurt A. Schalper, Roy S. Herbst, Katerina Politi
Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels
Biagio Ricciuti, Xinan Wang, Joao V. Alessi, Hira Rizvi, Navin R. Mahadevan, Yvonne Y. Li, Andrew Polio, James Lindsay, Renato Umeton, Rileen Sinha, Natalie I. Vokes, Gonzalo Recondo, Giuseppe Lamberti, Marissa Lawrence, Victor R. Vaz, Giulia C. Leonardi, Andrew J. Plodkowski, Hersh Gupta, Andrew D. Cherniack, Michael Tolstorukov, Bijaya Sharma, Kristen D. Felt, Justin F. Gainor, Arvind Ravi, Gad Getz, Kurt A. Schalper, Brian S. Henick, Patrick M. Forde, Valsamo Anagnostou, Pasi A. Jänne, Eliezer M. Van Allen, Mizuki Nishino, Lynette M. Sholl, David C. Christiani, Xihong Lin, Scott J. Rodig, Matthew D. Hellmann, Mark M. Awad
Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee
Mari Mino–Kenudson, Kurt A. Schalper, Wendy A. Cooper, Sanja Đačić, Fred R. Hirsch, Deepali Jain, Fernando López‐Ríos, Ming‐Sound Tsao, Yasushi Yatabe, Mary Beth Beasley, Hui Yu, Lynette M. Sholl, E. Brambilla, Teh‐Ying Chou, Casey Connolly, Ignacio I. Wistuba, Keith M. Kerr, Sylvie Lantuéjoul